My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
Grappling with 'Wicked Problems' in Alliance Management
Tell a Friend About This EventTell a Friend
Grappling with 'Wicked Problems' in Alliance Management

When: Thursday, October 24, 2019
12:00 to 1:00 PM EDT
Where: Online Webinar
United States
Contact: Brendan Ward

Online registration is closed.
« Go to Upcoming Event List  


"Wicked problems" are difficult to address because of incomplete, contradictory, and changing requirements. They are often difficult to recognize. And they can be difficult to discuss. We struggle to share our experiences with difficult problems involving complexity, uncertainty and conflict, especially when we were not able to resolve the issues. Surfacing the hard problems can teach our community the most.

These challenges arise throughout the alliance lifecycle and range from structural problems that come from company size, details in the contract, competing roles, portfolio versus individual program, organizational culture, and the many different assumptions that companies make about process and role. Add the dynamics that bedevil us, including team churn, joint steering committee roles, and meeting and decision-making behavior.

To the extent that we are better able to discuss difficulties (even failures) when stripped of identifying details, this session is based on a series of confidential interviews with senior leaders in alliance management who grapple with these problems and illustrate how seasoned alliance practitioners have approached them.

Bring your questions and be prepared to share your own reactions and suggestions. Leave with:

  • A heightened awareness of what makes some challenges especially difficult
  • A framework for thinking about wicked problems, how to engage them, and what resources you may need
  • Specific next steps that you can try when facing your own wicked problems

About the Speaker:

Jeremy Ahouse, CSAP, PhD
Vice President, Alliances
Merus, N.V.

Merus, a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, uses its proprietary Biclonics® technology to develop novel bispecific antibodies.

Jeremy is responsible for establishing Merus' alliance function and managing a broad research and clinical collaboration with Incyte and other current and future partners (e.g., Simcere, Institut Gustav Roussy). Since 1999 Jeremy has worked in pharmaceutical and biotech research and clinical collaborations with Celgene, Novartis, ImmunoGen, Vantage and Millennium.

Jeremy has served on the board of ASAP and helped to establish the CA-AM and CSAP exams. He contributed to the ASAP Best Practices Guide.

He earned his PhD in immunology and biophysics and held an HHMI post-doc in developmental genetics. He trained as a mediator and negotiator at Harvard's program on negotiation and has a keen interest in multiparty agreements and in how working together helps research and drug development by improving how we come to know–the epistemology of collaboration.

For more information email us at or call +1-781-562-1630